Friday, September 15, 2017 News Recap: President’s Report from HepCBC’s Annual General Meeting (AGM) HepCBC held its Annual General Meeting on September 12, 2017, and we are pleased to note that all the issues that we needed to address were covered. Rosemary Plummer has stepped down as president after 2 GREAT YEARS of service, but the rest of the Board of Directors has been re-elected, and some very important changes to our Constitution and Bylaws ...
A phase IIb open-label study of the combination of simeprevir, odalasvir and AL-335, also known as JNJ-4178, has been initiated by Janssen in treatment-naive and treatment-experienced subjects with chronic hepatitis C virus infection without cirrhosis. This global, multi-center study includes clinical trial sites in North America, Europe and Asia and forms part of Janssen’s global development program for JNJ-4178. The objectives of the phase IIb study are
- Ongoing Phase 2 development focusing on triple combination for treatment durations as short as six weeks for broad HCV population – PARIS, Sept. 23, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced that updated interim results were presented today in an ePoster describing a phase 2 study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) at the European Association for the Stu...
Simeprevir received two boosts on Nov. 12th: it is now listed on the Sasketchewan formulary (will be reimbursed by their public health insurance Pharmacare) and was also recommended highly by a Canadian Drug Review (CDR, CADTH, Health Canada) "Therapeutic Review" of hepatitis C DAA's (new Direct Acting Antiviral therapies) for HCV genotype 1. Details below: SASKATCHEWAN FORMULARY DETAILS: simeprevir, capsule, 150mg (Galexos-JAN) For the treatment of chroni
Simeprevir (GALEXOS) is also now covered on the Quebec formulary, according to CATIE, the Canadian AIDS Treatment Information Exchange. However, it is only available to those who have already failed conventional treatment with interferon and ribavirin. It is available only to genotype 1 patients who do not have the Q80K mutation and not co-infected with HIV. MUST MEET ALL THESE QUALIFICATIONS TO GET REIMBURSED FOR SIMEPREVIR: -- to be used in association w
Bangkok, Thailand, Feb. 28, 2014 (press release): "Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for equitable access to treatment for HCV, a curable infection t
Simeprevir (trade name Galexos) has now been approved for use in Canada. It is a once-daily pill which is taken along with ribavirin and pegylated interferon alfa to treat hepatitis C genotype 1 in a "triple therapy." There will still be many months before it is approved for coverage by your provincial Pharmacare plan. See details in complete Janssen Inc. Press Release below. ### New Treatment for Hepatitis C Approved by Health Canada Priority Review Give
On August 22nd, 2013 the Canadian Agency for Drugs and Technologies in Health (CADTH) released a call for patient input into Janssen Inc.'s new HCV drug, SIMEPREVIR. In order to prepare our Patient Group submission by the Sept. 13th deadline, HepCBC is ASKING for INPUT from HCV+ people and caregivers from throughout Canada, by Wednesday, Sept. 11th. CLICK HERE to ADD YOUR VOICE to HepCBC's group submission which will help determine whether this new treatme